Inovio Pharmaceuticals, Inc. (INO)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 13, 2025

$1.93

P/E Ratio

N/A

Market Cap

$73.28M

Loading...
Description
Add to research
View more

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Metrics
Add to research
View more

Overview

  • HQPlymouth Meeting, PA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerINO
  • Price$1.93-5.85%

Trading Information

  • Market cap$73.28M
  • Float99.31%
  • Average Daily Volume (1m)635,692
  • Average Daily Volume (3m)936,610
  • EPS-$4.48

Company

  • Revenue$0.20M
  • Rev growth (1yr)-100.00%
  • Net income-$25.17M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$26.58M
  • EV$90.29M
  • EV/Revenue443.89
  • P/EN/A
  • P/S267.00
  • P/B0.68
  • Debt/Equity16.92
Documents
Add to research
View more